These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 26480957

  • 1. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging.
    Kobayashi Y, Kobayashi H, Giles JT, Hirano M, Nakajima Y, Takei M.
    Int J Rheum Dis; 2016 Nov; 19(11):1169-1174. PubMed ID: 26480957
    [Abstract] [Full Text] [Related]

  • 2. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging.
    Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Nakajima Y, Takei M.
    J Rheumatol; 2014 Oct; 41(10):1916-21. PubMed ID: 25128513
    [Abstract] [Full Text] [Related]

  • 3. Impact of biological treatment on left ventricular dysfunction determined by global circumferential, longitudinal and radial strain values using cardiac magnetic resonance imaging in patients with rheumatoid arthritis.
    Yokoe I, Kobayashi H, Kobayashi Y, Nishiwaki A, Sugiyama K, Nagasawa Y, Ikumi N, Karasawa H, Okumura Y, Kitamura N, Takei M.
    Int J Rheum Dis; 2020 Oct; 23(10):1363-1371. PubMed ID: 32779338
    [Abstract] [Full Text] [Related]

  • 4. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF, Qushmaq K, Aljishi F.
    Ann Saudi Med; 2016 Oct; 36(3):190-6. PubMed ID: 27236390
    [Abstract] [Full Text] [Related]

  • 5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A.
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [Abstract] [Full Text] [Related]

  • 8. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L.
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [Abstract] [Full Text] [Related]

  • 9. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.
    Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F.
    Arthritis Care Res (Hoboken); 2015 Mar; 67(3):332-9. PubMed ID: 25186226
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype.
    Bissell LA, Erhayiem B, Hensor EMA, Fent G, Burska A, McDiarmid AK, Swoboda PP, Donica H, Plein S, Buch MH, Greenwood JP, Andrews J.
    Int J Cardiovasc Imaging; 2020 Mar; 36(3):491-501. PubMed ID: 32036488
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM.
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
    Addimanda O, Possemato N, Macchioni P, Salvarani C.
    Clin Exp Rheumatol; 2014 Oct; 32(4):460-4. PubMed ID: 24960220
    [Abstract] [Full Text] [Related]

  • 13. Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis.
    Kume K, Amano K, Yamada S, Hatta K, Kuwaba N, Ohta H.
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1477-81. PubMed ID: 21702090
    [Abstract] [Full Text] [Related]

  • 14. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J.
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [Abstract] [Full Text] [Related]

  • 15. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
    Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, Koike T, Nakamura H.
    Rheumatol Int; 2016 Mar; 36(3):349-57. PubMed ID: 26438386
    [Abstract] [Full Text] [Related]

  • 16. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL.
    Ter Arkh; 2013 Mar; 85(5):24-9. PubMed ID: 23819335
    [Abstract] [Full Text] [Related]

  • 17. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
    Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T.
    Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
    Ahmadzadeh A, Farahmand AN, Gachkar L.
    Int J Rheum Dis; 2017 Feb; 20(2):231-237. PubMed ID: 26385018
    [Abstract] [Full Text] [Related]

  • 19. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L, Steinberg G, Rouanet S, Combe B.
    Clin Exp Rheumatol; 2015 Feb; 33(5):664-70. PubMed ID: 26344671
    [Abstract] [Full Text] [Related]

  • 20. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T, Fujio K, Yamaoka K, Tomobe M, Kuroyanagi K, Kameda H.
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.